Track topics on Twitter Track topics that are important to you
Biosimilar acceptance among physicians has doubled to 80% since 2013, according to a survey presented at by copycat biologic distributor Celltrion Healthcare.
Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, ...
Michael JohnsenHospira, now a Pfizer company, entered into an agreement with Celltrion and Celltrion Healthcare in 2009 for several potential biosimilar products, including the recently-approved Infle...
Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson & Johnson (NYSE: JNJ) and Merck & Co (NYSE: MRK)...
Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute...
Pfizer and Celltrion still face patent questions – and a pesky launch notification issue – after the ground-breaking US approval of their biosimilar version of Janssen's Remicade.
Move over Zarxio, there's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a...
Celltrion will invest $275m at its biosimilar production site in Korea to ramp up capacity from 140,000L to 310,000L by 2021.